Published in Cancer Weekly, February 24th, 2004
Financial terms were not disclosed.
"This collaboration represents a significant step forward in Sirna's development of RNAi-based therapeutics and is our first alliance with a major pharmaceutical company," said Howard W. Robin, president and chief executive officer of Sirna Therapeutics.
"We chose Lilly as a partner based on Lilly's extensive expertise in developing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.